Literature DB >> 1323139

Immunoglobulins and complement components levels in patients with lung cancer.

J Gmiński1, J Mykała-Cieśla, M Machalski, M Drózdz, J Najda.   

Abstract

Sera from 96 patients with lung cancer were assayed in order to evaluate the concentrations of IgG, IgA, IgM, C3c and C4. Histologically, 49 of the patients had squamous cell carcinoma, 11--adenocarcinoma, 20--small cell carcinoma and 16--not identified lung cancer. No statistically significant differences were found between the concentrations of IgG and IgM in patients with carcinoma of the lung versus subjects in the control group. Both serum IgA and complement components (C30 and C4) were significantly elevated in almost all patients from the tumor group as compared with the levels in the control group.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1323139

Source DB:  PubMed          Journal:  Rom J Intern Med        ISSN: 1220-4749


  12 in total

Review 1.  Potential biomarkers for lung cancer screening.

Authors:  Gabriella Sozzi; Mattia Boeri
Journal:  Transl Lung Cancer Res       Date:  2014-06

Review 2.  Targeting complement-mediated immunoregulation for cancer immunotherapy.

Authors:  Martin Kolev; Maciej M Markiewski
Journal:  Semin Immunol       Date:  2018-02-15       Impact factor: 11.130

3.  Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.

Authors:  Daniel Ajona; María J Pajares; Leticia Corrales; Jose L Perez-Gracia; Jackeline Agorreta; Maria D Lozano; Wenceslao Torre; Pierre P Massion; Juan P de-Torres; Eloisa Jantus-Lewintre; Carlos Camps; Javier J Zulueta; Luis M Montuenga; Ruben Pio
Journal:  J Natl Cancer Inst       Date:  2013-08-12       Impact factor: 13.506

Review 4.  The role of complement in tumor growth.

Authors:  Ruben Pio; Leticia Corrales; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 5.  Complement and macrophage crosstalk during process of angiogenesis in tumor progression.

Authors:  M Afzal Khan; A M Assiri; D C Broering
Journal:  J Biomed Sci       Date:  2015-07-22       Impact factor: 8.410

6.  RACK1 is a candidate gene associated with the prognosis of patients with early stage non-small cell lung cancer.

Authors:  Yi-Young Choi; Shin Yup Lee; Won Kee Lee; Hyo-Sung Jeon; Eung Bae Lee; Hyun Cheol Lee; Jin Eun Choi; Hyo-Gyoung Kang; Eun Jin Lee; Eun Young Bae; Seung Soo Yoo; Jaehee Lee; Seung Ick Cha; Chang Ho Kim; In-San Kim; Myung Hoon Lee; Young Tae Kim; Sanghoon Jheon; Jae Yong Park
Journal:  Oncotarget       Date:  2015-02-28

7.  A Panel of Genetic Polymorphism for the Prediction of Prognosis in Patients with Early Stage Non-Small Cell Lung Cancer after Surgical Resection.

Authors:  Shin Yup Lee; Jin Eun Choi; Hyo-Sung Jeon; Yi-Young Choi; Won Kee Lee; Eung Bae Lee; Hyun Cheol Lee; Hyo-Gyoung Kang; Seung Soo Yoo; Jaehee Lee; Seung Ick Cha; Chang Ho Kim; Myung Hoon Lee; Young Tae Kim; Sanghoon Jheon; Jae Yong Park
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

8.  Development of a prognosis-prediction model incorporating genetic polymorphism with pathologic stage in stage I non-small cell lung cancer: A multicenter study.

Authors:  Won Kee Lee; Shin Yup Lee; Jin Eun Choi; Yangki Seok; Eung Bae Lee; Hyun Cheol Lee; Hyo-Gyoung Kang; Seung Soo Yoo; Myung Hoon Lee; Sukki Cho; Sanghoon Jheon; Young Chul Kim; In Jae Oh; Kook Joo Na; Chi Young Jung; Chang-Kwon Park; Mi-Hyun Kim; Min Ki Lee; Jae Yong Park
Journal:  Thorac Cancer       Date:  2017-03-31       Impact factor: 3.500

Review 9.  Complement inhibition in cancer therapy.

Authors:  Ruben Pio; Daniel Ajona; John D Lambris
Journal:  Semin Immunol       Date:  2013-05-24       Impact factor: 10.671

10.  Identification of Serum Peptidome Signatures of Non-Small Cell Lung Cancer.

Authors:  Agnieszka Klupczynska; Agata Swiatly; Joanna Hajduk; Jan Matysiak; Wojciech Dyszkiewicz; Krystian Pawlak; Zenon J Kokot
Journal:  Int J Mol Sci       Date:  2016-03-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.